Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

摘要: Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to development glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk hypoglycaemia. Lixisenatide is recommended as once-daily GLP-1 RA T2DM. In persons T2DM, lixisenatide 20 µg given by bolus subcutaneous injection improves secretion suppresses glucagon glucose-dependent manner. Compared longer-acting liraglutide, achieved significantly greater reduction postprandial plasma glucose (PPG) during standardized test breakfast T2DM otherwise insufficiently controlled on metformin alone. This primarily due inhibition gastric motility compared liraglutide. The efficacy safety was evaluated across spectrum series phase III, randomized, placebo-controlled trials known GetGoal programme. monotherapy or add-on oral antidiabetic agents basal significant reductions glycated haemoglobin, PPG fasting glucose, either weight loss no gain. most frequent adverse events were gastrointestinal transient nature. provides an easy, once-daily, single-dose, management little increased hypoglycaemia potential beneficial effect body weight.